New botulinum toxin aims to smooth frown lines in phase 2 trial
NCT ID NCT06481475
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests a new injection called YY003, a recombinant botulinum neurotoxin type A, for treating moderate to severe frown lines between the eyebrows (glabellar lines) in adults. Participants receive a single set of small injections into five points between the brows. The trial measures how well the treatment reduces frown line severity and tracks any side effects, including immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YY003 (recombinant botulinum neurotoxin type A)
What this could lead to
If successful, YY003 could offer a new option for temporarily smoothing frown lines, potentially with fewer side effects than current botulinum toxin products.
What could go wrong
This is an early phase 2 study with only 149 participants, so results may not apply to everyone. As with any injection, risks include bruising, pain, or temporary muscle weakness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE GLABELLAR LINES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Institute of Victoria
Melbourne, Victoria, 3141, Australia
-
Skin Health Institute
Melbourne, Victoria, 3053, Australia
-
St George Dermatology & Skin Cancer Centre
Sydney, New South Wales, 2217, Australia